United Quick Ratio vs Total Assets Analysis

UTHR Stock

USD 235.31 3.53 1.52%

United Therapeutics financial indicator trend analysis is much more than just breaking down United Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether United Therapeutics is a good investment. Please check the relationship between United Therapeutics Quick Ratio and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

Quick Ratio vs Total Assets

Quick Ratio vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of United Therapeutics Quick Ratio account and Total Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between United Therapeutics' Quick Ratio and Total Assets is 0.68. Overlapping area represents the amount of variation of Quick Ratio that can explain the historical movement of Total Assets in the same time period over historical financial statements of United Therapeutics, assuming nothing else is changed. The correlation between historical values of United Therapeutics' Quick Ratio and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Quick Ratio of United Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Quick Ratio i.e., United Therapeutics' Quick Ratio and Total Assets go up and down completely randomly.

Correlation Coefficient

0.68

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Quick Ratio

A measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities.

Total Assets

Total assets refers to the total amount of United Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in United Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from United Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.As of 04/18/2024, Enterprise Value is likely to grow to about 11.8 B, while Selling General Administrative is likely to drop slightly above 207.3 M.

	2021	2022	2023	2024 (projected)
Gross Profit	1.6B	1.8B	2.1B	2.2B
Total Revenue	1.7B	1.9B	2.3B	2.4B

Gross Profit Total Revenue

United Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Good Will	Common Stock Total Equity	Short Term Investments	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.84	0.24	0.64	1.0	0.97	-0.14	0.97	-0.22	0.85	0.99	0.33	0.92	0.74	0.24	0.56	0.89	-0.3	0.89	0.99	0.92	0.46	0.95	0.99	0.83	0.48
Short Long Term Debt Total	0.84		0.27	0.37	0.8	0.8	0.26	0.8	-0.25	0.61	0.86	0.2	0.9	0.43	0.13	0.82	0.77	-0.3	0.92	0.8	0.84	0.4	0.82	0.79	0.82	0.51
Other Current Liab	0.24	0.27		-0.24	0.22	0.23	-0.18	0.33	0.02	0.33	0.21	0.54	0.42	0.44	0.08	0.51	0.29	-0.55	0.27	0.26	0.23	0.39	0.14	0.19	0.4	0.09
Total Current Liabilities	0.64	0.37	-0.24		0.63	0.69	-0.31	0.57	-0.19	0.61	0.63	0.23	0.36	0.69	0.45	-0.09	0.56	0.02	0.58	0.62	0.48	0.42	0.53	0.65	0.47	0.24
Total Stockholder Equity	1.0	0.8	0.22	0.63		0.96	-0.19	0.98	-0.22	0.86	0.98	0.33	0.9	0.74	0.2	0.51	0.88	-0.31	0.85	0.99	0.91	0.42	0.95	0.99	0.81	0.47
Property Plant And Equipment Net	0.97	0.8	0.23	0.69	0.96		-0.18	0.94	-0.15	0.85	0.96	0.43	0.86	0.79	0.4	0.53	0.84	-0.31	0.9	0.96	0.92	0.61	0.88	0.96	0.82	0.55
Net Debt	-0.14	0.26	-0.18	-0.31	-0.19	-0.18		-0.26	0.12	-0.59	-0.04	-0.57	-0.01	-0.58	-0.1	0.39	-0.16	0.41	0.12	-0.23	-0.01	-0.27	0.06	-0.17	0.13	0.03
Retained Earnings	0.97	0.8	0.33	0.57	0.98	0.94	-0.26		-0.28	0.91	0.94	0.49	0.92	0.78	0.11	0.54	0.91	-0.5	0.83	0.98	0.92	0.45	0.89	0.94	0.75	0.54
Accounts Payable	-0.22	-0.25	0.02	-0.19	-0.22	-0.15	0.12	-0.28		-0.3	-0.19	-0.14	-0.3	-0.21	0.41	-0.11	-0.33	0.34	-0.2	-0.26	-0.13	0.06	-0.2	-0.2	0.02	0.05
Cash	0.85	0.61	0.33	0.61	0.86	0.85	-0.59	0.91	-0.3		0.79	0.63	0.77	0.86	0.2	0.35	0.8	-0.56	0.69	0.89	0.74	0.54	0.68	0.83	0.57	0.41
Non Current Assets Total	0.99	0.86	0.21	0.63	0.98	0.96	-0.04	0.94	-0.19	0.79		0.27	0.9	0.69	0.26	0.58	0.84	-0.25	0.91	0.95	0.92	0.44	0.93	0.97	0.86	0.49
Non Currrent Assets Other	0.33	0.2	0.54	0.23	0.33	0.43	-0.57	0.49	-0.14	0.63	0.27		0.37	0.66	0.07	0.21	0.42	-0.86	0.31	0.38	0.44	0.65	0.12	0.26	0.14	0.57
Cash And Short Term Investments	0.92	0.9	0.42	0.36	0.9	0.86	-0.01	0.92	-0.3	0.77	0.9	0.37		0.61	0.11	0.79	0.88	-0.44	0.9	0.91	0.89	0.45	0.89	0.88	0.76	0.44
Net Receivables	0.74	0.43	0.44	0.69	0.74	0.79	-0.58	0.78	-0.21	0.86	0.69	0.66	0.61		0.39	0.21	0.73	-0.48	0.63	0.77	0.59	0.64	0.54	0.74	0.56	0.26
Common Stock Shares Outstanding	0.24	0.13	0.08	0.45	0.2	0.4	-0.1	0.11	0.41	0.2	0.26	0.07	0.11	0.39		0.12	0.08	0.36	0.39	0.22	0.13	0.7	0.16	0.31	0.4	-0.07
Non Current Liabilities Total	0.56	0.82	0.51	-0.09	0.51	0.53	0.39	0.54	-0.11	0.35	0.58	0.21	0.79	0.21	0.12		0.53	-0.32	0.75	0.53	0.62	0.43	0.58	0.5	0.6	0.35
Other Current Assets	0.89	0.77	0.29	0.56	0.88	0.84	-0.16	0.91	-0.33	0.8	0.84	0.42	0.88	0.73	0.08	0.53		-0.46	0.81	0.92	0.8	0.4	0.86	0.86	0.65	0.39
Other Stockholder Equity	-0.3	-0.3	-0.55	0.02	-0.31	-0.31	0.41	-0.5	0.34	-0.56	-0.25	-0.86	-0.44	-0.48	0.36	-0.32	-0.46		-0.25	-0.35	-0.44	-0.29	-0.14	-0.21	-0.07	-0.54
Total Liab	0.89	0.92	0.27	0.58	0.85	0.9	0.12	0.83	-0.2	0.69	0.91	0.31	0.9	0.63	0.39	0.75	0.81	-0.25		0.85	0.84	0.59	0.83	0.86	0.82	0.46
Total Current Assets	0.99	0.8	0.26	0.62	0.99	0.96	-0.23	0.98	-0.26	0.89	0.95	0.38	0.91	0.77	0.22	0.53	0.92	-0.35	0.85		0.89	0.46	0.94	0.97	0.78	0.45
Good Will	0.92	0.84	0.23	0.48	0.91	0.92	-0.01	0.92	-0.13	0.74	0.92	0.44	0.89	0.59	0.13	0.62	0.8	-0.44	0.84	0.89		0.46	0.88	0.88	0.76	0.73
Common Stock Total Equity	0.46	0.4	0.39	0.42	0.42	0.61	-0.27	0.45	0.06	0.54	0.44	0.65	0.45	0.64	0.7	0.43	0.4	-0.29	0.59	0.46	0.46		0.3	0.46	0.46	0.32
Short Term Investments	0.95	0.82	0.14	0.53	0.95	0.88	0.06	0.89	-0.2	0.68	0.93	0.12	0.89	0.54	0.16	0.58	0.86	-0.14	0.83	0.94	0.88	0.3		0.94	0.81	0.42
Property Plant And Equipment Gross	0.99	0.79	0.19	0.65	0.99	0.96	-0.17	0.94	-0.2	0.83	0.97	0.26	0.88	0.74	0.31	0.5	0.86	-0.21	0.86	0.97	0.88	0.46	0.94		0.82	0.37
Short Term Debt	0.83	0.82	0.4	0.47	0.81	0.82	0.13	0.75	0.02	0.57	0.86	0.14	0.76	0.56	0.4	0.6	0.65	-0.07	0.82	0.78	0.76	0.46	0.81	0.82		0.35
Intangible Assets	0.48	0.51	0.09	0.24	0.47	0.55	0.03	0.54	0.05	0.41	0.49	0.57	0.44	0.26	-0.07	0.35	0.39	-0.54	0.46	0.45	0.73	0.32	0.42	0.37	0.35

Click cells to compare fundamentals

United Therapeutics Account Relationship Matchups

United Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Other Current Liab	39.6M	319.2M	301.6M	339.1M	71M	116.3M
Total Current Liabilities	463M	323.3M	305.4M	343.2M	804.4M	844.6M
Total Stockholder Equity	2.8B	3.4B	4.0B	4.8B	6.0B	6.3B
Property Plant And Equipment Net	738.5M	731.6M	780.9M	861.5M	1.0B	1.1B
Net Debt	111.6M	61.3M	(94.8M)	(161.2M)	(507.7M)	(482.3M)
Retained Earnings	3.3B	3.8B	4.3B	5.0B	6.0B	6.3B
Accounts Payable	23.1M	9.9M	4.1M	3.8M	5.6M	10.2M
Cash	738.4M	738.7M	894.8M	961.2M	1.2B	1.3B
Non Current Assets Total	2.0B	2.4B	2.8B	2.7B	3.6B	3.8B
Non Currrent Assets Other	154.6M	169.9M	108.2M	114.3M	151.8M	91.5M
Cash And Short Term Investments	2.3B	3.0B	3.6B	4.2B	3.0B	3.1B
Net Receivables	151.4M	157.4M	198.7M	220.4M	278.9M	292.8M
Common Stock Shares Outstanding	43.8M	44.6M	47.3M	48.5M	49.7M	50.7M
Liabilities And Stockholders Equity	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Non Current Liabilities Total	670M	896.5M	904.8M	904.6M	377.8M	269.4M
Other Current Assets	133.8M	88.3M	100.4M	219.2M	166.2M	174.5M
Other Stockholder Equity	(531.3M)	(430.5M)	(333.8M)	(190.8M)	(30.2M)	(28.7M)
Total Liab	1.1B	1.2B	1.2B	1.2B	1.2B	1.2B
Total Current Assets	1.9B	2.2B	2.3B	3.4B	3.6B	3.7B
Short Term Investments	747.5M	1.1B	1.0B	1.9B	1.8B	1.9B
Property Plant And Equipment Gross	738.5M	731M	1.1B	1.2B	1.5B	1.5B
Intangible Assets	130.3M	130.1M	16.6M	16.5M	80.5M	84.5M
Other Liab	67M	79.4M	104.8M	76.8M	88.3M	60.5M
Other Assets	293.8M	1.6B	370.1M	413.5M	475.5M	284.7M
Inventory	93.4M	86.5M	93.8M	102M	111.8M	55.9M
Property Plant Equipment	738.5M	731.6M	780.9M	861.5M	990.7M	1.0B
Net Tangible Assets	2.6B	3.2B	3.9B	4.8B	5.5B	5.7B
Retained Earnings Total Equity	3.3B	3.8B	4.3B	5.0B	5.8B	6.1B

United Therapeutics Investors Sentiment

The influence of United Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in United. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average United Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on United Therapeutics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards United Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, United Therapeutics' short interest history, or implied volatility extrapolated from United Therapeutics options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BAC	Bank of America
DD	Dupont De Nemours
F	Ford Motor

When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:

How To Invest In United

Details

Is United Stock a good investment?

Details

What is United Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for United Stock analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Commodity Directory Find actively traded commodities issued by global exchanges
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Global Correlations Find global opportunities by holding instruments from different markets
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios

Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.626

Earnings Share

19.82

Revenue Per Share

49.733

Quarterly Revenue Growth

0.251

Return On Assets

0.1122

The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

United Quick Ratio vs Total Assets Analysis

Quick Ratio vs Total Assets

Quick Ratio vs Total Assets Correlation Analysis

Correlation Coefficient

Quick Ratio

Total Assets

United Therapeutics fundamental ratios Correlations

United Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

United Therapeutics fundamental ratios Accounts

United Therapeutics Investors Sentiment

Also Currently Popular

Complementary Tools for United Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Total Stockholder Equity

Other Stockholder Equity	- 0.86	Non Currrent Assets Other
Cash	- 0.59	Net Debt
Net Receivables	- 0.58	Net Debt
Non Currrent Assets Other	- 0.57	Net Debt
Other Stockholder Equity	- 0.56	Cash
Other Stockholder Equity	- 0.55	Other Current Liab